EG01377 is a potent, bioavailable, and selective neuropilin-1 (NRP1) inhibitor with anti-angiogenic, anti-migratory, and anti-tumor activities; it inhibits VEGF-A-stimulated tyrosine phosphorylation of VEGF-R2/KDR, reduces HUVEC cell migration and VEGF-induced wound closure, suppresses vascular network formation, inhibits VEGF-induced angiogenesis, attenuates A375P malignant melanoma spheroid outgrowth in combination with VEGFA, and blocks TGFβ production by Nrp1+ regulatory T cells (Tregs) in the presence of tumor cell-derived factors.